69584-48-1Relevant articles and documents
ANTIDIABETIC COMPOUNDS
-
Page/Page column 104; 105, (2015/09/23)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Experimental and Calculated Activation Parameters for Ring Opening of the 1-Bicyclopentyl Radical: The Effect of Bridgehead Substituents
Della, Ernest W.,Pigou, Paul E.,Schiesser, Carl H.,Taylor, Dennis K.
, p. 4659 - 4664 (2007/10/02)
Ring opening of the 1-bicyclopentyl, 3-phenyl-1-bicyclopentyl, and 3-carbomethoxy-1-bicyclopentyl radicals has been studied by experiment and by molecular orbital theory.Our results indicate that the parent system 1a is extremely reluctant to ring open, with an energy barrier of at least 26 kcal mol-1.The ester- and phenyl-substituted radicals rearrange somewhat more readily, with barriers of about 25 and 21 kcal mol-1, respectively.This trend is also observed in the molecular orbital treatment of these processes.Previous reports that include radical rearrangements of this type must now be reconsidered in light of our new data.
